Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
Fuji
Farmers Insurance
Moodys
QuintilesIMS
Medtronic
Cantor Fitzgerald
Colorcon

Generated: February 15, 2019

DrugPatentWatch Database Preview

Insulin lispro protamine recombinant; insulin lispro recombinant - Generic Drug Details

« Back to Dashboard

What are the generic sources for insulin lispro protamine recombinant; insulin lispro recombinant and what is the scope of insulin lispro protamine recombinant; insulin lispro recombinant patent protection?

Insulin lispro protamine recombinant; insulin lispro recombinant is the generic ingredient in six branded drugs marketed by Lilly and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Insulin lispro protamine recombinant; insulin lispro recombinant has twelve patent family members in nine countries.

There are forty drug master file entries for insulin lispro protamine recombinant; insulin lispro recombinant. One supplier is listed for this compound.

Summary for insulin lispro protamine recombinant; insulin lispro recombinant
International Patents:12
US Patents:1
Tradenames:6
Applicants:1
NDAs:2
Drug Master File Entries: 40
Suppliers / Packagers: 1
Clinical Trials: 9
DailyMed Link:insulin lispro protamine recombinant; insulin lispro recombinant at DailyMed
Pharmacology for insulin lispro protamine recombinant; insulin lispro recombinant
Ingredient-typeInsulin
Drug ClassInsulin Analog

US Patents and Regulatory Information for insulin lispro protamine recombinant; insulin lispro recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG MIX 50/50 PEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-003 Dec 22, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-002 Sep 6, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for insulin lispro protamine recombinant; insulin lispro recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-002 Sep 6, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for insulin lispro protamine recombinant; insulin lispro recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90067-4 Sweden ➤ Sign Up PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
13/34 Ireland ➤ Sign Up PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
00596 Netherlands ➤ Sign Up PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
90029-5 Sweden ➤ Sign Up PRODUCT NAME: INSULIN DEGLUDEK
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Mallinckrodt
AstraZeneca
Medtronic
US Army
UBS
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.